Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

作者
Nirav Niranjan Shah,Richard Thomas Maziarz,Caron Alyce Jacobson,Patrick B. Johnston,Sunil Abhyankar,Iris Isufi,Miguel‐Angel Perales,Monalisa Ghosh,Matthew L. Ulrickson,Allison Claire Rosenthal,Javier L Munoz,Nancy M. Hardy,Aaron P. Rapoport,Reem Karmali,Farrukh Tauseef Awan,Matthew Stuart McKinney,Mitchell E. Horwitz,Matthew Alexander Lunning,Nathan Denlinger,Marek Ancukiewicz
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 68-68 被引量:8
标识
DOI:10.1182/blood-2024-208539
摘要

Background: Zamto-cel is an investigational autologous tandem CD20-CD19-directed non-cryopreserved CAR-T cell product administered as a fresh formulation to patients (pts) with relapsed/refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) in the DALY II USA clinical trial (NCT04792489), a multicenter, open label, single-arm Phase 2 study. Here, we report efficacy and safety outcomes as part of a pre-planned interim analysis of 59 evaluable patients and 69 patients in the safety population. Methods: Eligible adults had r/r DLBCL after at least 2 prior lines of treatment including anti-CD20 monoclonal antibody and anthracycline-containing regimen and measurable disease per Lugano 2014 classification. Zamto-cel was manufactured utilizing CliniMACS Prodigy® (Miltenyi Biotec), a closed, automated system with a 14-day vein-to-vein time and administered as a fresh formulation. Lymphodepletion chemotherapy was initiated during the manufacturing process (either cyclophosphamide/ fludarabine or bendamustine) prior to receiving a single dose of zamto-cel at a dose of 2.5x106 CAR T cells/kg on Day 0. The primary endpoint was overall response rate (ORR) defined as best overall response (BOR) of either complete response (CR) or partial response (PR). Secondary endpoints included complete response rate (CRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and CD19 and CD20 antigen expression at relapse. Results: As of March 29th, 2024, 69 pts received zamto-cel of which 59 were evaluable having received a fresh, conforming product and completed a minimum of 3 months follow-up. Median age was 63 years (range 25-85), 39 (66%) were male. Sixteen pts (27%) received 3 or more lines of prior treatment. The majority of pts (53%) had elevated LDH at study entry, and 49% had ≥ 2 extranodal lesions, indicative of a study population with advanced disease. No pts received any bridging therapy, in the week after apheresis and before lymphodepletion. Only 7 pts (12%) received bendamustine as lymphodepleting regimen. Successful manufacturing of a fresh, in specification product occurred in 91.3% out of 69 treated pts. Four patients received a cryopreserved formulation to permit time for comorbid condition management. The mean viability of the final product was 96.0% with 29.4 % transduction efficacy. No patient died or withdrew during the manufacturing process. The ORR in the evaluable patient population (n=59) as assessed by an Independent Radiology Committee (IRC) was 72.9% (95% CI, 59.7-83.6), with a CRR of 49.2% (95% CI,35.9-62.5). The 6 month and 12 month-PFS was 55% (95%CI, 41-67) and 42% (95%CI, 28-56), respectively; 12 month-OS was 72% (95%CI, 57-83). The median DOR was 11.4 months. All 69 treated pts were assessed for safety outcomes. Treatment-emergent adverse events (TEAEs) were mostly of grade 1-2, the majority of grade ≥ 3 were hematological. Thirty-two pts (46.4%) experienced cytokine release syndrome (CRS), all grade 1-2. Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 12 pts (17.4%), grade 1-2 (9 pts; 13.1%); grade 3 (3 pts; 4.3%). One patient experienced immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), which resolved after 2 days. Biopsies at progression were available in 24 pts. CD19-negative relapse (defined as H Score <100) was seen in 2 pts, CD20-negative relapse was observed in 3 pts. Only one patient experienced loss of both antigens compared to pre-treatment status, demonstrating that most lymphomas maintain target antigen expression at relapse after treatment with zamto-cel. Conclusion: This pre-planned interim analysis represents the first pivotal trial of a tandem CD20-CD19 directed non-cryopreserved CAR-T cell product for patients with third-line r/r DLBCL. The trial plans to enroll 100 evaluable patients and the final data will be presented upon study completion. Among the 59 evaluable patients at the interim analysis, there is encouraging activity and a favorable safety profile in DLBCL patients treated with zamto-cel. Unlike currently registered CAR-T cell products, zamto-cel is administered as a fresh product with a short vein-to-vein time of 14 days with lymphodepletion initiated during the manufacturing process. With a manufacturing success rate of 91% we have demonstrated the feasibility of this process among high-risk patients with r/r DLBCL.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaomage发布了新的文献求助10
刚刚
Akim的应助被顶刊相见采纳,获得30
刚刚
刚刚
xiao发布了新的文献求助10
刚刚
酷炫的成风完成签到,获得积分10
1秒前
1秒前
范阳完成签到,获得积分10
1秒前
迷你的乌冬面完成签到,获得积分10
1秒前
君为臣纲的应助被zx采纳,获得10
1秒前
ZZ完成签到 ,获得积分10
2秒前
所所的应助被handan采纳,获得10
2秒前
2秒前
momo19完成签到,获得积分10
2秒前
CC66发布了新的文献求助10
2秒前
宁阿霜完成签到,获得积分10
2秒前
zypazyp完成签到,获得积分10
3秒前
12345完成签到,获得积分10
3秒前
领导范儿的应助被满君清采纳,获得10
3秒前
liz完成签到,获得积分10
4秒前
wangxuan完成签到,获得积分10
4秒前
等待的花生完成签到,获得积分10
4秒前
斯文败类的应助被tourist585采纳,获得10
4秒前
液氧完成签到,获得积分10
5秒前
篱篱清完成签到,获得积分10
5秒前
杨璐源完成签到,获得积分20
5秒前
HaoTu完成签到,获得积分10
6秒前
文龙发布了新的文献求助10
6秒前
RRRenaissance完成签到,获得积分10
6秒前
shelemi发布了新的文献求助10
6秒前
6秒前
Yan完成签到 ,获得积分10
7秒前
7秒前
一二完成签到,获得积分10
7秒前
wangxiaolei完成签到,获得积分10
7秒前
复杂哲瀚完成签到,获得积分10
7秒前
zhaoxu完成签到,获得积分10
7秒前
仙贝完成签到,获得积分10
8秒前
lunekiss完成签到 ,获得积分10
8秒前
长欢完成签到 ,获得积分10
8秒前
xiatian发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105